Radcliffe Capital Management’s Tevogen Bio Warrant TVGNW Stock Holding History

Radcliffe Capital Management’s Portfolio TVGNW Stock Details TVGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-46,287	Closed	-$1.62K	–	88
2023 Q4	$1.62K	Sell	46,287 -153,713	-77%	-$6.24K	﹤0.01%	176
2023 Q3	$9.63K	Hold	200,000	–	–	﹤0.01%	348
2023 Q2	$8.29K	Hold	200,000	–	–	﹤0.01%	443
2023 Q1	$17K	Hold	200,000	–	–	﹤0.01%	453
2022 Q4	$2.07M	Hold	200,000	–	–	0.07%	452
2022 Q3	$2.03M	Hold	200,000	–	–	0.05%	626
2022 Q2	$2M	Hold	200,000	–	–	0.05%	666
2022 Q1	$2M	Buy	+200,000	New	+$74.4K	0.05%	643

Other funds holding TVGNW

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Radcliffe Capital Management's TVGNW Position: Q1 2024 in Review

Radcliffe Capital Management sold out of Tevogen Bio Warrant (TVGNW) in Q1 2024, closing a stake of 46,287 shares — an estimated $1.62K sold.

Radcliffe Capital Management first reported a position in TVGNW in Q1 2022 and held it in 8 quarters. The position peaked at $2.07M in Q4 2022. 41 funds tracked by Wall St. Rank hold TVGNW as of Q1 2024.

Radcliffe Capital Management reported no remaining Tevogen Bio Warrant position as of Q1 2024 after selling out during the quarter.
Radcliffe Capital Management sold 46,287 Tevogen Bio Warrant shares in Q1 2024, an estimated $1.62K.
Radcliffe Capital Management first reported a position in Tevogen Bio Warrant in Q1 2022 and held it in 8 quarters.
Radcliffe Capital Management's Tevogen Bio Warrant position peaked at $2.07M in Q4 2022.
41 funds tracked by Wall St. Rank held Tevogen Bio Warrant as of Q1 2024.

Based on Radcliffe Capital Management's 13F filing for Q1 2024, filed 15 May 2024.